Solanezumab and Gantenerumab Fail to Slow Memory Loss or Cognitive Decline in Early-onset Alzheimer’s, Study Finds

Solanezumab and Gantenerumab Fail to Slow Memory Loss or Cognitive Decline in Early-onset Alzheimer’s, Study Finds
Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in a Phase 2/3 clinical trial (NCT01760005). Despite these results, the data collected will prove useful for identifying biomarkers and improving understanding of early-onset Alzheimer’s and the more common form of the disease that develops after the age of 65 (late-onset), researchers said. “Although the drugs we evaluated were not successful, the trial will move us forward in understanding Alzheimer’s,” Randall J. Bateman, MD, the study's principal investigator and a neurology professor, said in a news story. Early-onset Alzheimer’s, also known as dominantly inherited Alzheimer’s disease, is an inherited form of the disease caused by a mutation in any one of three genes: PSEN1PSEN2, or APP. Although it is a rare form of the disease, early-onset Alzheimer's is similar in some ways to the late-onset form.
Subscribe or to access all post and page content.